- Conditions
- Substance-Related Disorders, Hepatitis
- Interventions
- Pegylated Interferon
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–185
of 185
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intervention for Nerve Agent Exposure
- Interventions
- Protexia
- Biological
- Lead sponsor
- PharmAthene, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CZP), Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
- Conditions
- Anemia
- Interventions
- Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 51 more
- Conditions
- ADHD, Controls
- Interventions
- Lidocaine gel, Placebo, Injected lidocaine
- Drug
- Lead sponsor
- PhenoSolve, LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Colonoscopy
- Interventions
- BLI-800, Polyethylene glycol 3350 based bowel preparation
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Washington D.C., District of Columbia • Jupiter, Florida + 8 more
- Conditions
- Influenza
- Interventions
- cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CDP870)
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
- Conditions
- HCV Infection
- Interventions
- placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 48
- States / cities
- Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Gender Dysphoria
- Interventions
- Polyethylene Glycol 3350
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Opioid Induced Constipation (OIC)
- Interventions
- placebo, NKTR-118
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
- Conditions
- Pediatric Immuno-Tolerant Chronic Hepatitis B
- Interventions
- Entecavir, Lamivudine, Pegylated Interferon Alfa-2A
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 3
- States / cities
- Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
- Interventions
- NTX-001 (PEG-Fusion)
- Combination Product
- Lead sponsor
- Neuraptive Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Los Angeles, California • San Francisco, California • Orlando, Florida + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 14
- States / cities
- Coronado, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Prostate Cancer, Kidney Cancer, Constipation
- Interventions
- Polyethylene Glycol 3350
- Drug
- Lead sponsor
- Chad R. Tracy
- Other
- Eligibility
- 30 Years to 100 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Systemic Allergic Reaction
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland